Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
10 hedge funds and large institutions have $25.8M invested in Anebulo Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
11% more funds holding
Funds holding: 9 → 10 (+1)
0.04% more ownership
Funds ownership: 17.92% → 17.96% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
6% less capital invested
Capital invested by funds: $27.5M → $25.8M (-$1.65M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2L
22NW LP
Seattle,
Washington
|
+$127K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$3.32K |
| 3 |
BlackRock
New York
|
+$1.33K |
| 4 |
Morgan Stanley
New York
|
+$13 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$62.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.78K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
2L
1
22NW LP
Seattle,
Washington
| $20.7M | +$127K | +19,148 | +0.6% |
|
|
MP
2
Mangrove Partners
Greenwich,
Connecticut
| $2.5M | -$62.9K | -9,487 | -2% |
|
|
LCM
3
Laurion Capital Management
New York
| $1.4M | – | – | – |
|
|
IC
4
Ikarian Capital
Dallas,
Texas
| $1.07M | – | – | – |
|
|
BFM
5
Boothbay Fund Management
New York
| $110K | – | – | – |
|
|
6
BlackRock
New York
| $49K | +$1.33K | +200 | +3% |
|
|
7
UBS Group
Zurich,
Switzerland
| $4K | -$1.78K | -268 | -32% |
|
|
8
Osaic Holdings
Scottsdale,
Arizona
| $3K | +$3.32K | +500 | New |
|
|
9
Morgan Stanley
New York
| – | +$13 | +2 | New |
|
ANEB Hedge Fund Activity: Q4 2021 in Review
10 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q4 2021, worth a combined $25.8M — down 6% from $27.5M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ANEB positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was 22NW LP, adding an estimated $127K. The largest seller was Mangrove Partners, cutting an estimated $62.9K.
- 10 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q4 2021, up from 9 in Q3 2021.
- Funds reported $25.8M of Anebulo Pharmaceuticals stock for Q4 2021, down 6% quarter-over-quarter.
- 2 funds opened new Anebulo Pharmaceuticals positions in Q4 2021 and 1 closed out, a net change of +1 holder.
- The largest Anebulo Pharmaceuticals buyer in Q4 2021 was 22NW LP, an estimated $127K added.
- The largest Anebulo Pharmaceuticals seller in Q4 2021 was Mangrove Partners, an estimated $62.9K sold.
Based on aggregated 13F filings for Q4 2021.